Hikma Pharmaceuticals has reported a 9% revenue growth in 2024 and strategically acquired assets from Xellia Pharmaceuticals and Takeda to strengthen its portfolio and market position.

Target Information

Hikma Pharmaceuticals PLC, a multinational pharmaceutical company based in Amman, Jordan, announced its audited financial results for the year ending December 31, 2024. The group experienced a revenue growth of 9% (9% in constant currency), reaching $3.127 billion, compared to $2.875 billion in 2023. In 2024, Hikma has demonstrated solid financial performance that exceeded expectations, driven by strong momentum across its three business sectors.

The company has strategically invested in research and development, enhancing its diverse product pipeline while improving its manufacturing capabilities and market presence. Hikma is the seventh largest supplier of generic pharmaceuticals in the United States and the third largest supplier of injectable generics by volume in this market. Moreover, for the second consecutive year, Hikma has maintained its position as the second largest pharmaceutical company in the Middle East and North Africa based on sales.

Industry Overview in Jordan

The pharmaceutical industry in Jordan has shown resilience and growth, supported by a favorable regulatory environment and increasing demand for healthcare products. The sector ha